Home   Search   Browse   Statistics   User guide   FAQs   Post question   Download   Process data  
Search results for the GEO ID: GSE22250
(Click on the check boxes provided under "Select for analysis", to initiate grouping)
(Once the selection is made, click on "Add groups" in "Make groups for comparison", to make a group. Scroll down)
GSM ID
GPL ID
Select for analysis
Title
Source name
Description
Characteristics
GSM553873
GPL570
Normal breast cell line MCF10A (expression data) Normal breast cell line conditions: Normal treatment protocol: None growth protocol: MCF10A WT cells were maintained in DMEM/F12 (1:1) medium (Gibco) supplemented with 10% fetal calf serum (Gibco). cell line: MCF10A
GSM553874
GPL570
Breast cancer cell line MCF-7 WT (expression data) Breast cancer cell line conditions: WT treatment protocol: Cells were harvested after 5 or 6 passages. They were detached from the culture flask using a cell scraper. growth protocol: MCF-7 WT cells were maintained in DMEM medium (Gibco) supplemented with 10% fetal calf serum (Gibco). cell line: MCF-7
GSM553875
GPL570
Breast cancer cell line MCF-7 5-AZA (expression data) Breast cancer cell line conditions: 5-AZA treatment protocol: Cells were treated with 5-aza-2’-deoxycytidine (1µM) during 4 days before being harvested. They were detached from the culture flask using a cell scraper. growth protocol: MCF-7 5-AZA cells were maintained in DMEM medium (Gibco) supplemented with 10% fetal calf serum (Gibco). Cells were treated with 5-aza-2’-deoxycytidine (1µM) during 4 days. The medium was refreshed every day. cell line: MCF-7 agent: 5-AZA
GSM553876
GPL570
Breast cancer cell line T47D WT (expression data) Breast cancer cell line conditions: WT treatment protocol: Cells were harvested after 5 or 6 passages. They were detached from the culture flask using a cell scraper. growth protocol: T47D WT cells were maintained in RPMI medium (Gibco) supplemented with 10% fetal calf serum (Gibco). cell line: T47D
GSM553877
GPL570
Breast cancer cell line T47D 5 AZA (expression data) Breast cancer cell line conditions: 5-AZA treatment protocol: Cells were treated with 5-aza-2’-deoxycytidine (1µM) during 4 days before being harvested. They were detached from the culture flask using a cell scraper. growth protocol: T47D 5-AZA cells were maintained in RPMI medium (Gibco) supplemented with 10% fetal calf serum (Gibco). Cells were treated with 5-aza-2’-deoxycytidine (1µM) during 4 days. The medium was refreshed every day. cell line: T47D agent: 5-AZA
GSM553878
GPL570
Breast cancer cell line SKBR3 WT (expression data) Breast cancer cell line conditions: WT treatment protocol: Cells were harvested after 5 or 6 passages. They were detached from the culture flask using a cell scraper. growth protocol: SKBR3 WT cells were maintained in DMEM medium (Gibco) supplemented with 10% fetal calf serum (Gibco). cell line: SKBR3
GSM553879
GPL570
Breast cancer cell line SKBR3 5 AZA (expression data) Breast cancer cell line conditions: 5-AZA treatment protocol: Cells were treated with 5-aza-2’-deoxycytidine (1µM) during 4 days before being harvested. They were detached from the culture flask using a cell scraper. growth protocol: SKBR3 5-AZA cells were maintained in DMEM medium (Gibco) supplemented with 10% fetal calf serum (Gibco). Cells were treated with 5-aza-2’-deoxycytidine (1µM) during 4 days. The medium was refreshed every day. cell line: SKBR3 agent: 5-AZA
GSM553880
GPL570
Breast cancer cell line BT20 WT (expression data) Breast cancer cell line conditions: WT treatment protocol: Cells were harvested after 5 or 6 passages. They were detached from the culture flask using a cell scraper. growth protocol: BT20 WT cells were maintained in MEM medium (Gibco) supplemented with 10% fetal calf serum (Gibco). cell line: BT20
GSM553881
GPL570
Breast cancer cell line BT20 5 AZA (expression data) Breast cancer cell line conditions: 5-AZA treatment protocol: Cells were treated with 5-aza-2’-deoxycytidine (1µM) during 4 days before being harvested. They were detached from the culture flask using a cell scraper. growth protocol: BT20 5-AZA cells were maintained in MEM medium (Gibco) supplemented with 10% fetal calf serum (Gibco). Cells were treated with 5-aza-2’-deoxycytidine (1µM) during 4 days. The medium was refreshed every day. cell line: BT20 agent: 5-AZA
GSM553882
GPL570
Breast cancer cell line MDA-MB-231 WT (expression data) Breast cancer cell line conditions: WT treatment protocol: Cells were harvested after 5 or 6 passages. They were detached from the culture flask using a cell scraper. growth protocol: MDA-MB-231 WT cells were maintained in DMEM medium (Gibco) supplemented with 10% fetal calf serum (Gibco). cell line: MDA-MB-231
GSM553883
GPL570
Breast cancer cell line MDA-MB-231 5 AZA (expression data) Breast cancer cell line conditions: 5-AZA treatment protocol: Cells were treated with 5-aza-2’-deoxycytidine (1µM) during 4 days before being harvested. They were detached from the culture flask using a cell scraper. growth protocol: MDA-MB-231 5-AZA cells were maintained in DMEM medium (Gibco) supplemented with 10% fetal calf serum (Gibco). Cells were treated with 5-aza-2’-deoxycytidine (1µM) during 4 days. The medium was refreshed every day cell line: MDA-MB-231 agent: 5-AZA
GSM553884
GPL570
Breast cancer cell line MDA-MB-361 WT (expression data) Breast cancer cell line conditions: WT treatment protocol: Cells were harvested after 5 or 6 passages. They were detached from the culture flask using a cell scraper. growth protocol: MDA-MB-361 WT cells were maintained in RPMI medium (Gibco) supplemented with 10% fetal calf serum (Gibco). cell line: MDA-MB-361
GSM553885
GPL570
Breast cancer cell line MDA-MB-361 5 AZA (expression data) Breast cancer cell line conditions: 5-AZA treatment protocol: Cells were treated with 5-aza-2’-deoxycytidine (1µM) during 4 days before being harvested. They were detached from the culture flask using a cell scraper. growth protocol: MDA-MB-361 5-AZA cells were maintained in RPMI medium (Gibco) supplemented with 10% fetal calf serum (Gibco). Cells were treated with 5-aza-2’-deoxycytidine (1µM) during 4 days. The medium was refreshed every day. cell line: MDA-MB-361 agent: 5-AZA
GSM553886
GPL570
Breast cancer cell line ZR-75-1 WT (expression data) Breast cancer cell line conditions: WT treatment protocol: Cells were harvested after 5 or 6 passages. They were detached from the culture flask using a cell scraper. growth protocol: ZR-75-1 WT cells were maintained in RPMI medium (Gibco) supplemented with 10% fetal calf serum (Gibco). cell line: ZR-75-1
GSM553887
GPL570
Breast cancer cell line ZR-75-1 5 AZA (expression data) Breast cancer cell line conditions: 5-AZA treatment protocol: Cells were treated with 5-aza-2’-deoxycytidine (1µM) during 4 days before being harvested. They were detached from the culture flask using a cell scraper. growth protocol: ZR-75-1 5-AZA cells were maintained in RPMI medium (Gibco) supplemented with 10% fetal calf serum (Gibco). Cells were treated with 5-aza-2’-deoxycytidine (1µM) during 4 days. The medium was refreshed every day. cell line: ZR-75-1 agent: 5-AZA
GSM553888
GPL570
Normal lymphoid cell line WEIS3E5 (expression data) Normal lymphoid cell line conditions: Normal treatment protocol: The WEIS3E5 cells were harvested after 3 days of growth growth protocol: The normal CD8+ lymphoid cell line WEIS3E5 was maintained in Isocove Dubelcco medium supplemented with 10% human serum HS54, L-Arginine, L-Asparagine, L-glutamine, 2-mercaptoéthanol and methyltryptophane as well as with 10 ng/mL of IL-7 and 50 U/mL of IL-2. cell line: WEIS3E5
GSM553889
GPL570
ex vivo B lymphocytes (expression data) ex vivo B lymphocytes conditions: ex vivo treatment protocol: Ex vivo B lymphocytes were isolated from blood sample of a patient with hemochromatosis using CD20 antibody coupled to magnetic beads (Miltenyi Biotec). growth protocol: None cell type: ex vivo B lymphocytes
GSM553890
GPL570
ex vivo T lymphocytes (expression data) ex vivo T lymphocytes conditions: ex vivo treatment protocol: Ex vivo T lymphocytes were isolated from blood sample of a patient with hemochromatosis using CD3 antibody coupled to magnetic beads (Miltenyi Biotec). growth protocol: None cell type: ex vivo T lymphocytes
 
 
Make groups for comparisons
(2 groups will be compared at a time)
Select GSMs and click on "Add groups"
Enter the group name here:


Select expression type
Transcripts profile based on;
A. Differential status (Up/Down regulation)
B. Absolute calls (Transcribed/Not-detected)
 
Filter results by number of probes